Millon Clinical Multiaxial Inventory

From WikiMD's WELLNESSPEDIA

Millon Clinical Multiaxial Inventory (MCMI) is a psychological assessment tool used by clinicians to identify the presence of psychopathology, including specific personality disorders. It was developed by Theodore Millon, an American psychologist known for his work on personality disorders.

Overview[edit]

The Millon Clinical Multiaxial Inventory is a comprehensive self-report test that provides information on a person's emotional, behavioral, and interpersonal characteristics. The MCMI is based on Millon's theory of personality and psychopathology, and it is designed to help clinicians diagnose mental health disorders, formulate treatment plans, and monitor treatment progress.

Development and Structure[edit]

The MCMI was first published in 1983, with subsequent editions (MCMI-II, MCMI-III) incorporating updates to reflect changes in the Diagnostic and Statistical Manual of Mental Disorders (DSM). The MCMI-III, the most recent version, contains 175 items and 28 scales: 24 clinical personality patterns and 4 severe personality pathology scales.

Use in Clinical Practice[edit]

The MCMI is used in a variety of clinical settings, including psychiatric hospitals, outpatient clinics, and counseling centers. It is intended for use with adults (18 years and older) who are undergoing psychiatric assessment or treatment. The MCMI is not designed for use with nonclinical populations or for the purpose of employment screening.

Criticisms and Controversies[edit]

While the MCMI is widely used in clinical practice, it has been the subject of some criticism. Some researchers have questioned the validity of the MCMI's scales and the accuracy of its diagnostic algorithms. Others have raised concerns about the potential for overdiagnosis of personality disorders.

See Also[edit]

References[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.